An Open-Label, Multicenter Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Eculizumab in Pediatric Patients With Refractory Generalized Myasthenia Gravis
Phase of Trial: Phase III
Latest Information Update: 23 Nov 2019
Price : $35 *
At a glance
- Drugs Eculizumab (Primary)
- Indications Myasthenia gravis
- Focus Registrational; Therapeutic Use
- Sponsors Alexion Pharmaceuticals
- 24 Jul 2019 According to an Alexion Pharmaceuticals media release, dosing is underway in this study.
- 28 Mar 2019 Status changed from not yet recruiting to recruiting.
- 25 Jan 2019 Planned number of patients changed from 12 to 17.